Work

Vini Vidi Stenti

Year: 2022
Type: editorial
Abstract: n a recent issue of the Journal of the American Heart Association (JAHA), Reinhard and colleagues presented an interesting cohort series of people enrolled at 2 Danish centers undergoing renal artery stenting.1 As described by the authors, they established their registry after the reporting of the CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions), ASTRAL (Angioplasty and Stenting for Renal Artery Lesions), and STAR (Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis) randomized trials and enrolled people with ≥70% renal artery stenosis in predominantly 3 groups: those with hypertension not yet controlled; those with declining renal function; and, finally, a subgroup with heart failure.Of the 102 patients, 5 were not treated because of an occluded renal artery, and there were 12 procedure-related complications, including 4 significant renal artery injuries, 2 renal artery emboli, 2 respiratory events requiring intensive care, and 4 access site pseudoaneurysms.Over a median of 2 years, the serious adverse event rate was high.Ten died and 5 initiated renal replacement therapy, including 1 who started dialysis 2 days after stenting, and another 5 underwent contralateral nephrectomy for blood pressure control.Furthermore, of the 5 patients who had unsuccessful attempts at stenting, 4 died within 6 months, and the other required renal replacement therapy.
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,700
OpenAlex ID: W4292323849
Cites: 18
Cited by:
Related to: 9